NCT02063295View on ClinicalTrials.gov

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

ObesityOver-weightHypothalamic InjuryCraniopharyngioma

Interventions

DRUG

ZGN-440 sterile diluent

ZGN-440 sterile diluent/placebo

DRUG

ZGN-440 for injectable suspension

Trial Locations (4)

2006

The Boden Institute, Sydney

3081

Austin Health, Metabolic Disorders Centre, Heidelberg Heights

37232

Vanderbilt University Medical Center, Nashville

55102

Children's Hospitals and Clinics of Minnesota, Saint Paul

All Listed Sponsors

lead

Zafgen, Inc.

INDUSTRY

NCT02063295 - An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury | Biotech Hunter | Biotech Hunter